News and Trends 13 Oct 2022 Odyssey Therapeutics raises $168M for oncology medicine portfolio Biotech company Odyssey Therapeutics, Inc. has announced it has raised $168 million in series B financing. Odyssey Therapeutics is working on next generation precision immunomodulators and oncology medicines. The current round brings the total capital raised to $386 million. The proceeds will enable Odyssey to advance its portfolio of precision immunomodulators and oncology medicines in […] October 13, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Oct 2022 Merck contributing to Jacobio Pharma colorectal cancer clinical trial Jacobio announced it has entered into a clinical trial collaboration agreement with Merck on a clinical study of combination therapy between Jacobio’s KRAS G12C inhibitor JAB-21822 and Merck’s epidermal growth factor receptor (EGFR) inhibitor Erbitux (cetuximab). This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated […] October 13, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Oct 2022 T-cell therapy platform trial begins in adults with blood cancers SMART102, a human T-lymphoid progenitor cell injection derived from cord blood using Smart Immune’s ProTcell platform, has entered clinical testing. The trial is being sponsored and led by Great Paris University Hospitals (AP-HP). Smart Immune SAS is a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T-cell therapy platform to fully and rapidly re-arm the immune […] October 13, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Oct 2022 Skin microbiome research could lead to new approaches for addressing organ damage after stem cell transplants Skin microbiome research could lead to new approaches for addressing organ damage after stem cell transplants. Organ damage occurs in up to 70% of patients in the first few months following stem cell transplant. The reasons for this potentially life-threatening reaction have long been the subject of scientific research. Now, researchers led by Georg Stary […] October 13, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Oct 2022 Inotrem says septic shock trial yields positive results Clinical stage biotech company Inotrem has announced results from its phase IIb ASTONISH clinical trial in septic shock patients. The results were revealed at the International Sepsis Forum in Barcelona, Spain. Study details ASTONISH was designed to show the efficacy of nangibotide in septic shock with a precision medicine approach aiming to identify patients who […] October 13, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Oct 2022 Adalta and GPCR Therapeutics to collaborate on novel cancer treatments AdAlta Limited and GPCR Therapeutics Inc, are set to collaborate to evaluate AdAlta’s CXCR4 inhibiting i‑bodies as cancer therapeutics, using GPCR Therapeutics’ combination inhibition approach. AdAlta said its i-body platform is suited to engaging an important class of drug targets called G-protein coupled receptors (GPCRs). One of these GPCRs is known as CXCR4. In addition […] October 13, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2022 Amolyt Pharma publishes hypoparathyroidism treatment results Amolyt Pharma has announced positive results from the second patient cohort in its phase 2a clinical proof of concept trial of AZP-3601, a PTH1 receptor agonist, which the company is developing as a potential treatment for hypoparathyroidism. Consistent with the findings from cohort 1, in the full data set from the phase 2a study, AZP-3601 […] October 12, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2022 SiSaf takes steps with FDA for RNA therapeutic to treat rare genetic skeletal disorders SiSaf Ltd, an RNA delivery and therapeutics company, is initiating the U.S. FDA Regulatory process to obtain orphan drug designation for SIS-101-ADO. SIS-101-ADO is a siRNA therapeutic for patients with autosomal dominant osteopetrosis type 2 (ADO2), a rare genetic skeletal disorder. The request for orphan drug designation and advancement through the regulatory process that SIS-101-ADO […] October 12, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2022 Ascidian Therapeutics launches with $50M to rewrite RNA Ascidian Therapeutics, a biotechnology company focused on treating human diseases by rewriting RNA, has been launched. With an initial focus on replacing mutated exons at the RNA level, Ascidian’s technology enables therapeutic targeting of large genes and genes with high mutational variance while maintaining native gene expression patterns and levels. This approach is designed to […] October 12, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2022 Malaysian Genomics signs research agreement with government MGRC Therapeutics Sdn Bhd (MGRC-T), a wholly-owned subsidiary of Malaysian Genomics Resource Centre Berhad, has entered into a cooperation agreement with the National Institutes of Health, Malaysia (NIH). The agreement provides a framework for collaboration between the two parties in medical research pertaining to genomics and biopharmaceuticals. The National Institutes of Health (NIH), the research […] October 12, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2022 Virtual trials growth leads to Cambridge Cognition acquiring eClinicalHealth Cambridge Cognition is looking to accelerate its growth through the acquisition of eClinicalHealth Ltd (eCH). Cambridge Cognition is an active player in the central nervous system (CNS) market, supplying digital solutions to assess brain health. eCH is a full-service digital technology provider working on virtual clinical trials for three of the world’s top 10 largest […] October 12, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2022 Emergex looks to microneedle patches with Zosano Pharma acquisition Emergex Vaccines Holding Limited has acquired the assets of California-based company Zosano Pharma Corporation. Emergex is a clinical stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines. The assets acquired include intellectual property, license agreements, and manufacturing equipment. They also include Zosano’s proprietary microneedle array […] October 12, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email